Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

  • STATUS
    Not Recruiting
  • participants needed
    175
  • sponsor
    Novartis Pharmaceuticals
Updated on 20 June 2021
Investigator
Novartis Pharmaceuticals
Primary Contact
Novartis Investigative Site (9.2 mi away) Contact
+17 other location
cancer
measurable disease
carcinoma
solid tumour
endometrial carcinoma
advanced melanoma

Summary

The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.

Description

Combined treatment with MCS110 and PDR001 is expected to result in TAM depletion, enhanced T-cell activation and synergistic antitumor activity in the clinical setting.

Details
Condition Pancreatic Cancer, Endometrial Carcinoma, Uterine Cancer, Breast Cancer, melanoma, skin cancer, Diet and Nutrition, Chronic Diarrhea, Skin Wounds, Metastatic Melanoma, Chronic Shoulder Pain, Vaginal Atrophy, Adverse Effects, Drugs, Injection Port, Breast Cancer - HER2 Positive, Anal Dysplasia, Primary Immunodeficiency, Pediatric Health, Near-Sighted Corrective Surgery, Peripheral Arterial Occlusive Disease, Triple Negative Breast Cancer, Brain Function, Recurrent Respiratory Papillomatosis, Razor Bumps (Pseudofolliculitis Barbae), Islet Ce417ll Cancer, Metastatic Triple-Negative Breast Cancer, Endometrial Cancer, Malignant Melanoma
Treatment PDR001, MCS110
Clinical Study IdentifierNCT02807844
SponsorNovartis Pharmaceuticals
Last Modified on20 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note